CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $8.37M, lower than 95% of all stocks globally
- PositionGross margin is 10.4%, lower than 95% of its Biotechnology peers (median 67.1%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
748.60MUSDvs all stocks (USD)
Revenue (TTM)
8.37MUSDvs all stocks (USD)
Beta
0.7690xvs all stocks
52-Week Change
248.44%vs all stocks
Market Capitalization
748.60MUSDvs all stocks (USD)
Enterprise Value
645.17MUSDvs all stocks (USD)
Forward P/E
-6.47xvs Biotechnology peers
Price to Sales (TTM)
89.47xvs Biotechnology peers
Price to Book (MRQ)
5.21xvs Biotechnology peers
Enterprise to Revenue
77.11xvs Biotechnology peers
Enterprise to EBITDA
-8.22xvs Biotechnology peers
Gross Margin
10.42%vs Biotechnology peers
Operating Margin
-1111.82%vs Biotechnology peers
Return on Assets (TTM)
-24.72%vs Biotechnology peers
Return on Equity (TTM)
-48.42%vs Biotechnology peers
Revenue (TTM)
8.37MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0670USDUpdated Jul 17, 2026Quarterly Revenue Growth
37.20%vs Biotechnology peers
Gross Profit (TTM)
-55.91MUSDvs all stocks (USD)
EBITDA (TTM)
-78.47MUSDvs all stocks (USD)
Net Income (TTM)
-69.66MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
37.18%vs Biotechnology peers
Operating Cash Flow (TTM)
-52.20MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-32.21MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 17, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
7.83MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
7.28MUSDFY2025 · Dec 31, 2025Gross Profit
542.00KUSDFY2025 · Dec 31, 2025Operating Income
-70.26MUSDvs all stocks (USD)
Pre-tax Income
-64.92MUSDFY2025 · Dec 31, 2025Net Income
-64.92MUSDFY2025 · Dec 31, 2025EBIT
-70.26MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-67.51MUSDFY2025 · Dec 31, 2025Research & Development
52.65MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
21.97MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-3.81MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
7.64MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-64.92MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-45.15MUSDFY2025 · Dec 31, 2025Free Cash Flow
-45.27MUSDDerived from operating cash flow minus capital expenditure. This filing charges 454K of depreciation against 111K of capital expenditure, and its own free-cash-flow line reads -47.22M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
19.96MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-64.92MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
454.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
12.38MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.30MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
8.45MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-3.82MUSDFY2025 · Dec 31, 2025Capital Expenditures
-111.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00USDFY2025 · Dec 31, 2025Net Acquisitions
-833.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-39.73MUSDFY2025 · Dec 31, 2025Sale of Investments
89.04MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
48.37MUSDFY2025 · Dec 31, 2025Other Financing Charges
-5.86MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-5.86MUSDFY2025 · Dec 31, 2025Shares Outstanding
139.65MSharesUpdated Jul 17, 2026Float Shares
113.14MSharesUpdated Jul 17, 2026Shares Short
11.40MSharesUpdated Jul 17, 2026Short Ratio
5.76daysvs all stocks
Short % of Shares Outstanding
9.34%vs all stocks
% Held by Insiders
2.28%vs all stocks
% Held by Institutions
79.64%vs all stocks
Total Cash (MRQ)
105.42MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.7550USDUpdated Jul 17, 2026Total Debt (MRQ)
1.99MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0138xvs Biotechnology peers
Current Ratio (MRQ)
4.03xvs Biotechnology peers
Book Value per Share (MRQ)
1.03USDUpdated Jul 17, 2026Total Assets
160.46MUSDvs all stocks (USD)
Total Current Assets
96.32MUSDFY2025 · Dec 31, 2025Total Liabilities
57.38MUSDFY2025 · Dec 31, 2025Total Non-current Assets
64.14MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
28.73MUSDFY2025 · Dec 31, 2025Total Current Liabilities
28.64MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
19.96MUSDFY2025 · Dec 31, 2025Other Short-term Investments
70.79MUSDFY2025 · Dec 31, 2025Accounts Payable
13.16MUSDFY2025 · Dec 31, 2025Deferred Revenue
3.94MUSDFY2025 · Dec 31, 2025Other Current Liabilities
2.75MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
12.56MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-967.78MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
103.08MUSDvs all stocks (USD)
52-Week Low
1.46USDUpdated Jul 17, 202652-Week High
5.85USDUpdated Jul 17, 202652-Week Change
248.44%vs all stocks
Beta
0.7690xvs all stocks
50-Day MA
4.82USDUpdated Jul 17, 2026200-Day MA
3.54USDUpdated Jul 17, 2026Avg 10-Day Volume
1.92MSharesUpdated Jul 17, 2026Avg 30-Day Volume
1.98MSharesUpdated Jul 17, 2026Diluted EPS (TTM)
-0.5400USDUpdated Jul 17, 2026Other Income / Expense
-2.30MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 10.4%, lower than 95% of its Biotechnology peers (median 67.1%)Significant
Gross margin: 0.10Industry median: 0.67Industry P5: 0.14Peers compared: 261
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 4.03Altman Z-Score: -1.51
Financial Health
Altman Z-Score -1.51: distress zoneCritical
Altman Z-Score: -1.51
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $8.37M, lower than 95% of all stocks globallySignificant
Revenue (USD): 8,367,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Rigel Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Bright Minds Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Candel Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Monopar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Neurogene Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zevra Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Lianhuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhuzhou Qianjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Sanyou Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Oculis Holding AG
Tier 1ProductionApproval-Gated PipelineRule